IL17RA and psoriasis: Of note, Brodalumab, the only approved anti-IL17RA drug for psoriasis, demonstrated superiority over ustekinumab in achieving Psoriasis Area Severity Index (PASI) 100 at week 12 in AMAGINE-2 and AMAGINE-3 clinical trials and a multicenter study involving 606 patients further showed that 91.3% of patients achieved a PASI score of 2 or less after 3 years of Brodalumab treatment (13, 14).